Calamos Advisors LLC Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Calamos Advisors LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 167,950 shares of the medical research company’s stock after buying an additional 228 shares during the quarter. Calamos Advisors LLC’s holdings in Edwards Lifesciences were worth $12,433,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. GDS Wealth Management boosted its holdings in Edwards Lifesciences by 46.2% during the 4th quarter. GDS Wealth Management now owns 191,013 shares of the medical research company’s stock valued at $14,141,000 after acquiring an additional 60,339 shares during the period. Boston Trust Walden Corp boosted its stake in shares of Edwards Lifesciences by 88.6% in the fourth quarter. Boston Trust Walden Corp now owns 282,372 shares of the medical research company’s stock valued at $20,904,000 after purchasing an additional 132,629 shares during the period. Financial Life Planners purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $89,000. Jennison Associates LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $555,939,000. Finally, Resonant Capital Advisors LLC lifted its holdings in Edwards Lifesciences by 8.0% during the 4th quarter. Resonant Capital Advisors LLC now owns 3,382 shares of the medical research company’s stock worth $250,000 after buying an additional 250 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on EW. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. Barclays upped their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. JPMorgan Chase & Co. raised their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and an average target price of $79.19.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,000 shares of company stock worth $547,430 in the last quarter. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Trading Down 0.1 %

NYSE EW opened at $71.33 on Wednesday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The firm has a market cap of $42.07 billion, a PE ratio of 10.29, a P/E/G ratio of 3.72 and a beta of 1.11. The firm’s fifty day moving average is $72.49 and its two-hundred day moving average is $69.63. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.